4.6 Article

The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jamia/ocw148

关键词

precision medicine; database; cancer genomics; clinical reporting; pathology; application-programming interface

资金

  1. National Science Foundation [DB1054964]
  2. National Institutes of Health [R01CA194547]
  3. Hirschl Trust

向作者/读者索取更多资源

Objective: This paper describes the Precision Medicine Knowledge Base (PMKB; https://pmkb.weill.cornell.edu), an interactive online application for collaborative editing, maintenance, and sharing of structured clinical-grade cancer mutation interpretations. Materials and Methods: PMKB was built using the Ruby on Rails Web application framework. Leveraging existing standards such as the Human Genome Variation Society variant description format, we implemented a data model that links variants to tumor-specific and tissue-specific interpretations. Key features of PMKB include support for all major variant types, standardized authentication, distinct user roles including high-level approvers, and detailed activity history. A REpresentational State Transfer (REST) application-programming interface (API) was implemented to query the PMKB programmatically. Results: At the time of writing, PMKB contains 457 variant descriptions with 281 clinical-grade interpretations. The EGFR, BRAF, KRAS, and KIT genes are associated with the largest numbers of interpretable variants. PMKB's interpretations have been used in over 1500 AmpliSeq tests and 750 whole-exome sequencing tests. The interpretations are accessed either directly via the Web interface or programmatically via the existing API. Discussion: An accurate and up-to-date knowledge base of genomic alterations of clinical significance is critical to the success of precision medicine programs. The open-access, programmatically accessible PMKB represents an important attempt at creating such a resource in the field of oncology. Conclusion: The PMKB was designed to help collect and maintain clinical-grade mutation interpretations and facilitate reporting for clinical cancer genomic testing. The PMKB was also designed to enable the creation of clinical cancer genomics automated reporting pipelines via an API.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Veterinary Sciences

Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component

Simone de Brot, Jennifer Lothion-Roy, Llorenc Grau-Roma, Emily White, Franco Guscetti, Mark A. Rubin, Nigel P. Mongan

Summary: The histomorphology and expression of neuroendocrine markers in canine prostate cancer show specific features, associated with inflammation and urothelial differentiation. The study reports for the first time the expression of the neuroendocrine marker NSE and the finding of intraductal carcinoma of the prostate in dogs with prostate cancer.

VETERINARY AND COMPARATIVE ONCOLOGY (2022)

Article Chemistry, Multidisciplinary

Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors

Matthew J. Mosquera, Sungwoong Kim, Rohan Bareja, Zhou Fang, Shuangyi Cai, Heng Pan, Muhammad Asad, Maria Laura Martin, Michael Sigouros, Florencia M. Rowdo, Sarah Ackermann, Jared Capuano, Jacob Bernheim, Cynthia Cheung, Ashley Doane, Nicholas Brady, Richa Singh, David S. Rickman, Varun Prabhu, Joshua E. Allen, Loredana Puca, Ahmet F. Coskun, Mark A. Rubin, Himisha Beltran, Juan Miguel Mosquera, Olivier Elemento, Ankur Singh

Summary: This study defined the role of ECM signals in the development of CRPC-NEPC and identified potential therapeutic targets for neuroendocrine prostate cancer. In animal models, strong anti-tumor responses were observed with the use of a DRD2 inhibitor, and a combination of epigenetic inhibitors and DRD2 treatment was shown to overcome therapeutic resistance in CRPC-NEPC under drug-resistant ECM conditions.

ADVANCED MATERIALS (2022)

Review Oncology

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings

Ursula M. Vogl, Tomasz M. Beer, Ian D. Davis, Neal D. Shore, Christopher J. Sweeney, Piet Ost, Gerhardt Attard, Alberto Bossi, Johann de Bono, Charles G. Drake, Eleni Efstathiou, Stefano Fanti, Karim Fizazi, Susan Halabi, Nicolas James, Nicolas Mottet, Anwar R. Padhani, Mack Roach, Mark Rubin, Oliver Sartor, Eric Small, Matthew R. Smith, Howard Soule, Matthew R. Sydes, Bertrand Tombal, Aurelius Omlin, Silke Gillessen

Summary: This article discusses the lack of consensus on clinical management issues in advanced prostate cancer addressed at the Advanced Prostate Cancer Consensus Conference. By reviewing ongoing clinical trials, it is found that many unresolved questions remain. The article emphasizes that the lack of consensus indicates gaps in existing evidence and calls for robust clinical trials to fill these gaps.

EUROPEAN JOURNAL OF CANCER (2022)

Article Urology & Nephrology

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Ngozi Ekeke Onyeanunam, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin

Summary: This article discusses the optimal management of advanced prostate cancer patients during the COVID-19 pandemic. The study results indicate a consensus for full COVID-19 vaccination and booster injection, and the vaccination status influences the expert's treatment recommendations. Additionally, there is strong support for the use of telemedicine in monitoring patients.

EUROPEAN UROLOGY (2022)

Article Oncology

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients

Chantal Pauli, Lamberto De Boni, Jonathan E. Pauwels, Yanjiang Chen, Lara Planas-Paz, Reid Shaw, Brooke M. Emerling, Carla Grandori, Benjamin D. Hopkins, Mark A. Rubin

Summary: In this study, a functional precision oncology approach was implemented to identify tumor-specific drug sensitivities for patients with rare tumor types such as myxofibro-sarcoma. Comprehensive genomic profiling and high-throughput drug screening were used to identify therapeutic options and validate them in patient-derived xenograft models. Targeting the cell cycle was found to be a powerful approach in these tumors.

MOLECULAR CANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci

Jacqueline Fontugne, Peter Y. Cai, Hussein Alnajar, Bhavneet Bhinder, Kyung Park, Huihui Ye, Shaham Beg, Verena Sailer, Javed Siddiqui, Mirjam Blattner-Johnson, Jaclyn A. Croyle, Zohal Noorzad, Carla Calagua, Theresa Y. MacDonald, Ulrika Axcrona, Mari Bogaard, Karol Axcrona, Douglas S. Scherr, Martin G. Sanda, Bjarne Johannessen, Arul M. Chinnaiyan, Olivier Elemento, Rolf Skotheim, Mark A. Rubin, Christopher E. Barbieri, Juan Miguel Mosquera

Summary: Prostate cancer is a multifocal disease with distinct molecular subtypes. This study reveals the presence of inter- and intrafocal molecular heterogeneity in primary prostate cancer, with approximately 60% of multifocal specimens showing discordant molecular alterations between foci. Collision tumors, characterized by discrepant molecular status within a single focus, are identified in about 10% of the specimens. These findings highlight the complexity of molecular heterogeneity in prostate cancer and have important implications for future genomic studies.

JCI INSIGHT (2022)

Review Veterinary Sciences

Comparative pathology of dog and human prostate cancer

Toby Ryman-Tubb, Jennifer H. Lothion-Roy, Veronika M. Metzler, Anna E. Harris, Brian D. Robinson, Albert A. Rizvanov, Jennie N. Jeyapalan, Victoria H. James, Gary England, Catrin S. Rutland, Jenny L. Persson, Lukas Kenner, Mark A. Rubin, Nigel P. Mongan, Simone de Brot

Summary: Prostate cancer is relatively rare in dogs but is the most common non-cutaneous cancer in men. Canine prostate cancer has been proposed as a model for understanding prostate cancer in men due to the similarities in functional, anatomical, and physiological features. The necessity to better understand the mechanisms of prostate cancer initiation and progression to develop novel therapeutic approaches is urgent, particularly in the context of castrate-resistant prostate cancer in men.

VETERINARY MEDICINE AND SCIENCE (2022)

Article Urology & Nephrology

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin

Summary: The voting results from the 2021 Advanced Prostate Cancer Consensus Conference provide guidance for clinicians and patients in the management of advanced prostate cancer where evidence is scarce. However, treatment decisions should be individualized based on patient characteristics and current clinical evidence.

EUROPEAN UROLOGY (2022)

Correction Urology & Nephrology

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (vol 82, pg 6, 2022)

Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Onyeanunam Ngozi Ekeke, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin

EUROPEAN UROLOGY (2022)

Article Oncology

Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies

Joanna Cyrta, Davide Prandi, Arshi Arora, Daniel H. Hovelson, Andrea Sboner, Antonio Rodriguez, Tarcisio Fedrizzi, Himisha Beltran, Dan R. Robinson, Anuradha Gopalan, Lawrence True, Peter S. Nelson, Brian D. Robinson, Juan Miguel Mosquera, Scott A. Tomlins, Ronglai Shen, Francesca Demichelis, Mark A. Rubin

Summary: This study compares the pathological and molecular features of primary prostate cancer (PCa) and metastases, revealing their heterogeneity. The results highlight the importance of comprehensive immunohistochemistry-assisted pathology review and genomic analysis in determining the "index" area of primary PCa.

JOURNAL OF PATHOLOGY (2022)

Review Endocrinology & Metabolism

The evolving landscape of prostate cancer somatic mutations

Kellie Cotter, Mark A. Rubin

Summary: In recent years, the landscape of somatic mutations in prostate cancer (PCa) has rapidly evolved with the improvement in genomic sequencing platforms. However, there are still limitations in the current knowledge, such as low coverage and incomplete coverage of the mutation spectrum. Some alterations require DNA and RNA analysis for accurate frequency detection, and most studies rely on bulk PCa tumor samples without considering tumor heterogeneity.

PROSTATE (2022)

Article Pathology

Towards a national strategy for digital pathology in Switzerland

Andrew Janowczyk, Daniel Baumhoer, Stefan Dirnhofer, Rainer Grobholz, Anja Kipar, Laurence de Leval, Doron Merkler, Olivier Michielin, Holger Moch, Aurel Perren, Sven Rottenberg, Laura Rubbia-Brandt, Mark A. Rubin, Christine Sempoux, Markus Tolnay, Inti Zlobec, Viktor Hendrik Koelzer

Summary: Precision medicine is advancing into a new era of digital diagnostics, with the potential for integrated digital pathology and clinical data to drive biomedical research and business development. The creation of a Swiss Digital Pathology Infrastructure aims to establish a unified national network and facilitate international research collaboration, ultimately improving patient care through precision medicine.

VIRCHOWS ARCHIV (2022)

Review Oncology

Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future

Dilara Akhoundova, Mark A. Rubin

Summary: Next-generation DNA sequencing technology has greatly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, leading to personalized cancer treatment. Recent developments in tumor profiling now enable us to understand the molecular architecture and functional phenotype of tumors at the cellular and subcellular resolution.

CANCER CELL (2022)

Article Oncology

Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations

Alison M. Ferguson, Mark A. Rubin

Summary: The emergence of small cell prostate cancer is associated with tumor cell plasticity and evasion of environmental pressures. In-depth understanding of tumor plasticity can be achieved through clinical cohorts and disease progression models. Studying the tumor microenvironment and earlier time points can provide a comprehensive understanding and potentially lead to better patient outcomes by intervening early to reverse plasticity and prevent transition to the aggressive small cell phenotype.

CANCER LETTERS (2022)

Article Oncology

Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology

Carolyn C. Compton, Angelo M. De Mario, Jayanta Debnath, Keith D. Eaton, Kojo Elenitoba-Johnson, Michelangelo Fiorentino, Christopher A. French, Thomas J. Fuchs, Felice Giangaspero, Jiaoti Huang, A. John Lafrate, Michael M. Ittmann, Roy A. Jensen, Annette S. Kim, Massimo Loda, Robin G. Lorenz, Tamara L. Lotan, Anirban Maitre, Gerrit A. Meijer, Richard N. Mitchell, Anil Parwani, Francesco Pezzella, Eli Pikarsky, Jorge S. Reis-Filho, Andrea L. Richardson, Mark A. Rubin, Lawrence D. True

Summary: This article highlights the crucial role of pathologists in oncology practice and cancer research, focusing on their involvement in a patient's journey in cancer care.

CLINICAL CANCER RESEARCH (2022)

暂无数据